|
Mar 3
|
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Feb 28
|
C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
|
|
Feb 27
|
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Feb 27
|
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 27
|
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
|
|
Feb 26
|
C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Feb 24
|
C4 Therapeutics to Participate in Upcoming March Investor Conferences
|
|
Jan 2
|
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now
|
|
Dec 30
|
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?
|
|
Oct 9
|
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
|
|
Sep 3
|
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
|
|
May 22
|
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth
|
|
May 10
|
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations
|
|
May 8
|
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Apr 29
|
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 9
|
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
|
|
Apr 8
|
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 28
|
Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
|
|
Mar 5
|
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 4
|
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
|